Ovid Therapeutics (OVID) Depreciation and Depletion (2016 - 2026)
Ovid Therapeutics (OVID) posted Depreciation and Depletion of $35000.0 for Q1 2026, little changed on a QoQ basis from $35000.0 in Q4 2025, and down 59.77% year-over-year from $87000.0 in Q1 2025.
Ovid Therapeutics (OVID) Depreciation and Depletion (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Depreciation and Depletion history runs 11 years deep, the most recent figure standing at $35000.0 for Q1 2026.
- Quarterly Depreciation and Depletion fell 59.77% year-over-year to $35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148000.0 (down 61.66% YoY) and the FY2025 annual result came in at $200000.0, down 50.0% from the prior year.
- Depreciation and Depletion was $35000.0 for Q1 2026 at Ovid Therapeutics, roughly flat from $35000.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $131632.0 in Q4 2022 and bottomed at $17000.0 in Q3 2025.
- A 5-year average of $79598.4 and a median of $91000.0 in 2024 frame the typical range for Depreciation and Depletion.
- Annual changes were most pronounced in 2022 — Depreciation and Depletion surged 518.72% — and 2025, when it sank 83.81%.
- Ovid Therapeutics' Depreciation and Depletion stood at $131632.0 in 2022, then plunged by 37.71% to $82000.0 in 2023, then gained by 10.98% to $91000.0 in 2024, then plunged by 61.54% to $35000.0 in 2025, then changed by 0.0% to $35000.0 in 2026.
- Business Quant data shows OVID's Depreciation and Depletion at $35000.0 in Q1 2026, $35000.0 in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | - |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - | 35,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,000.00 |
| Mar 31, 2026 | 35,000.00 |
| Dec 31, 2025 | 35,000.00 |
| Dec 31, 2025 | 35,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Dec 31, 2024 | 91,000.00 |
| Sep 30, 2024 | 105,000.00 |
| Sep 30, 2024 | 105,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Jun 30, 2024 | 103,000.00 |
| Mar 31, 2024 | 101,000.00 |
| Mar 31, 2024 | 101,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Dec 31, 2023 | 82,000.00 |